Clinical Trial Update: PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib [Phase 2]

View source ↗

Summary

The document describes the completion of a Phase 2 clinical trial of PTK787/ZK222584 for metastatic gastrointestinal stromal tumors resistant to imatinib.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• PTK787/ZK222584 (vatalanib)

Snippet

Sponsor: University of Helsinki | Conditions: Sarcoma | Phase 2 | Status: COMPLETED